Skip to content
type1.science

Golimumab (anti-TNF)

Janssen (Simponi; repurposed)

An anti-TNF monoclonal antibody tested in the T1GER phase-2 trial in children and young adults with new-onset T1D. It preserved C-peptide and reduced insulin use over one year, with off-therapy follow-up signals, but it is not approved for T1D and has not proven stage-1/2 prevention.

Years awayModerate evidenceimmunotherapyrepurposedanti-tnfmonoclonal-antibodybeta-cell-preservation

The scorecard

Delay of onset48

New-onset T1GER preserved C-peptide at 52 weeks, but it has not been shown to delay clinical onset in stage-1/2 disease.[1]

Durability45

Two-year follow-up reported continued off-therapy metabolic improvements, but the evidence base remains one main phase-2 program.[2]

Safety52

Anti-TNF drugs have broad inflammatory-disease experience, but infection risk and chronic immune suppression are important concerns for young T1D patients.[4]

Stage breadth25

Tested in new-onset stage 3 only; no presymptomatic prevention trial has established stage-1/2 benefit.[3]

Access & cost20

Marketed for other autoimmune diseases but not T1D; diabetes use is investigational/off-label and biologic pricing limits reach.[4]

Editor’s take

Golimumab is too important to omit: T1GER was a clean pediatric/young-adult signal that anti-TNF biology can preserve beta-cell function. But it is still a repurposed chronic biologic with safety and access baggage, not a practical prevention tool yet.

The full picture

What it tested

Golimumab is an antibody against tumor necrosis factor alpha (TNF-alpha), a major inflammatory cytokine. The T1GER study tested whether blocking TNF soon after diagnosis could preserve the beta cells that remain.

Evidence and limits

T1GER randomized 84 children and young adults aged 6-21 with new-onset T1D to golimumab or placebo for 52 weeks. C-peptide was significantly higher with golimumab at week 52, insulin use was lower, and partial remission was more common.1

This is beta-cell preservation, not a demonstrated prevention of T1D onset. Anti-TNF therapy also carries chronic immune-suppression considerations that weigh heavily when the candidate population is young and otherwise healthy.

References

  1. Quattrin T, et al. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. New England Journal of Medicine (2020). https://doi.org/10.1056/NEJMoa2006136 ↩

Coming soon

ETA · Investigational for T1D; no active pivotal T1D program found in this pass

Sources

  1. [1]Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes · peer-reviewed · 2020-11-19 — PMID 33207093. Phase 2; n=84; ages 6-21; 4-hour C-peptide AUC at week 52 0.64 vs 0.43 pmol/mL (P<0.001).
  2. [2]Two-Year Follow-up From the T1GER Study · peer-reviewed · 2023-03-01 — PMID 36576974. Off-therapy metabolic follow-up after golimumab.
  3. [3]A Study of SIMPONI to Arrest Beta-cell Loss in Type 1 Diabetes · registry · 2025-02-04 — ClinicalTrials.gov NCT02846545; completed; actual enrollment 84.
  4. [4]SIMPONI (golimumab) prescribing information · regulatory · 2019-10-01 — FDA label for approved non-T1D indications; no T1D indication.